![](https://endpts.com/wp-content/uploads/2023/07/Frank-Stonebanks-Jeff-Keyser-Renibus-tile.jpg)
Renibus Therapeutics co-CEOs Frank Stonebanks (L) and Jeff Keyser
Renibus brings Series B total to $72M, securing registrational development for lead heart surgery candidate
Cardiorenal biotech Renibus Therapeutics has completed a Series B extension that brings its total proceeds to $72 million, securing a runway through registrational development and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.